Cdc7-IN-5 |
| Catalog No.GC62427 |
Cdc7-IN-5 (composé I-B) est un puissant inhibiteur de la kinase Cdc7 extrait du brevet WO2019165473A1, composé I-B. Cdc7 est une enzyme sérine-thréonine protéine kinase qui est essentielle pour l'initiation de la réplication de l'ADN dans le cycle cellulaire.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1402057-86-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Cdc7-IN-5 (compound I-B) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle[1].
[1]. Christian Andrew HASSIG, et al. Methods of treatment of cancer comprising cdc7 inhibitors. WO2019165473A1.
Average Rating: 5 (Based on Reviews and 37 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *